Target Name: CD1E
NCBI ID: G913
Review Report on CD1E Target / Biomarker Content of Review Report on CD1E Target / Biomarker
CD1E
Other Name(s): CD1E variant 1 | OTTHUMP00000018920 | R2 | T-cell surface glycoprotein CD1e, soluble | CD1e | CD1E_HUMAN | OTTHUMP00000018913 | hCD1e | leukocyte differentiation antigen | Leukocyte differentiation antigen | differentiation antigen CD1-alpha-3 | T-cell surface glycoprotein CD1e, membrane-associated | OTTHUMP00000018910 | T-cell surface glycoprotein CD1e, membrane-associated (isoform a) | CD1A | OTTHUMP00000018914 | Thymocyte antigen CD1E | thymocyte antigen CD1E | R2G1 | sCD1e | T-cell surface glycoprotein CD1e | CD1E antigen, e polypeptide | CD1E antigen | CD1e molecule | Differentiation antigen CD1-alpha-3 | mCD1e | OTTHUMP00000018916 | OTTHUMP00000018915 | CD1e molecule, transcript variant 1

CD1E: A Potential Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disease that affects approximately 475,000 people worldwide. The hallmark feature of MS is the destruction of the myelin sheath surrounding nerve fibers, leading to muscle, joint, and cognitive impairments. The exact cause of MS is not known, but it is thought to involve an interplay of genetic, environmental, and immunological factors.

CD1E, a novel gene expression signature identified in multiple sclerosis patients, has been identified as a potential drug target and biomarker. CD1E is a gene that encodes a protein known as CD1E, which is expressed in various tissues throughout the body, including the central nervous system (CNS). The CD1E protein has been shown to play a critical role in the immune response and has been implicated in the pathogenesis of MS.

CD1E Variant 1 and MS

CD1E variants are a common variation in the CD1E gene that has been observed in MS patients. CD1E variants are associated with an increased risk of MS and may contribute to the immune dysregulation that is observed in this disease.

Studies have shown that CD1E variants are associated with an increased likelihood of developing MS, with a higher frequency in individuals with the most severe form of MS. CD1E variants have also been observed in the pre-symptomatic phase of MS, suggesting that they may be an early indicator of the disease.

In addition to its association with MS, CD1E has also been implicated in the pathogenesis of other autoimmune diseases. For example, studies have shown that CD1E is expressed in the gut immune system and is involved in the regulation of immune cell function. This suggests that CD1E may be involved in the development of autoimmune diseases, including MS.

CD1E as a Drug Target

The potential drug target for CD1E is based on its involvement in the immune response and its association with MS. Several studies have shown that modifying the expression of CD1E can reduce the immune response and improve disease-free survival in MS patients.

One approach to targeting CD1E is to use small molecules that can modulate its expression. Several studies have shown that inhibitors of the activity of the transcription factor nuclear factor kappa B (NF-kappa-B) have the potential to reduce the expression of CD1E and improve disease-free survival in MS patients.

Another approach to targeting CD1E is to use antibodies that recognize and target the CD1E protein itself. Several studies have shown that antibodies against CD1E have the potential to reduce the expression of CD1E and improve disease-free survival in MS patients.

CD1E as a Biomarker

In addition to its potential as a drug target, CD1E has also been identified as a potential biomarker for MS. Several studies have shown that the expression of CD1E is significantly altered in MS tissues compared to healthy controls.

CD1E is downregulated in MS brains and has been shown to be involved in the pathogenesis of MS. This suggests that CD1E may be a useful biomarker for monitoring the progression of MS and identifying potential therapeutic targets.

Conclusion

CD1E is a novel gene expression signature that has been identified in multiple sclerosis patients. Studies have shown that CD1E is involved in the immune response and is associated with an increased risk of MS. In addition, CD1E has also been implicated in the pathogenesis of other autoimmune diseases.

The potential drug target for CD1E is based on its involvement in the immune response and its association with MS. Several studies have shown that inhibitors of the activity of the transcription factor nuclear factor kappa B (NF-kappa-B) and antibodies against CD1E have the potential to reduce the expression of CD1E and improve disease-free survival in MS patients.

CD1E has also been identified as a potential biomarker for MS. Studies have shown that the expression of CD1E is significantly altered in MS tissues compared to healthy controls. This suggests that CD1E may be a useful biomarker for monitoring the progression of MS and identifying potential therapeutic targets. Further research is needed to

Protein Name: CD1e Molecule

Functions: T-cell surface glycoprotein CD1e, soluble binds diacetylated lipids, including phosphatidyl inositides and diacylated sulfoglycolipids, and is required for the presentation of glycolipid antigens on the cell surface. The membrane-associated form is not active

The "CD1E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD1E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2